AJANTA PHARMA Financial Statement Analysis
|
||
|
The Revenues of AJANTA PHARMA have increased by 12.45% YoY .
The Earnings Per Share (EPS) of AJANTA PHARMA has increased by 38.82 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
AJANTA PHARMA Last 5 Annual Financial Results
[BOM: 532331|NSE : AJANTPHARM]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹4,209 Cr | ₹3,743 Cr | ₹3,341 Cr | ₹2,890 Cr | ₹2,588 Cr |
| Expenses | ₹3,037 Cr | ₹2,959 Cr | ₹2,412 Cr | ₹1,891 Cr | ₹1,905 Cr |
| Operating Profit (Excl OI) | ₹1,172 Cr | ₹783 Cr | ₹929 Cr | ₹999 Cr | ₹683 Cr |
| Other Income | ₹85 Cr | ₹99 Cr | ₹116 Cr | ₹26 Cr | ₹92 Cr |
| Interest | ₹7.21 Cr | ₹5.84 Cr | ₹10 Cr | ₹8.27 Cr | ₹12 Cr |
| Depreciation | ₹135 Cr | ₹131 Cr | ₹125 Cr | ₹116 Cr | ₹96 Cr |
| Profit Before Tax | ₹1,114 Cr | ₹745 Cr | ₹909 Cr | ₹900 Cr | ₹664 Cr |
| Profit After Tax | ₹816 Cr | ₹588 Cr | ₹713 Cr | ₹654 Cr | ₹468 Cr |
| Consolidated Net Profit | ₹816 Cr | ₹588 Cr | ₹713 Cr | ₹654 Cr | ₹468 Cr |
| Earnings Per Share (Rs) | ₹64.83 | ₹46.70 | ₹83.45 | ₹75.59 | ₹53.60 |
| PAT Margin (%) | 10.23 | 8.20 | 20.99 | 22.17 | 18.07 |
| ROE(%) | 23.49 | 17.68 | 22.77 | 23.38 | 19.32 |
| ROCE(%) | 32.22 | 22.57 | 29.37 | 32.20 | 27.44 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
Key Financials |
||
| Market Cap | : | ₹ 33,951.6 Cr |
| Revenue (TTM) | : | ₹ 4,531.8 Cr |
| Net Profit(TTM) | : | ₹ 897.9 Cr |
| EPS (TTM) | : | ₹ 71.9 |
| P/E (TTM) | : | 37.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AJANTA PHARMA | 5.7% | -5.3% | 24.4% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.2% | -5.8% | 22.9% |
| CIPLA | 1.3% | -4.8% | 9.5% |
| DR REDDYS LABORATORIES | 2.2% | -10.9% | -0.6% |
| ZYDUS LIFESCIENCES | 7% | -0.2% | 27.5% |
| DIVIS LABORATORIES | 4.1% | -7% | 52% |
| MANKIND PHARMA | 0.9% | -15.6% | 21.9% |
| TORRENT PHARMACEUTICALS | -3.3% | -5.7% | 28.7% |
| LUPIN | 1.6% | -13.2% | 38.3% |
AJANTA PHARMA Revenues
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 12.45 % |
| 5 Yr CAGR | 12.93 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹4,209 Cr | 12.45 | |
| Mar2023 | ₹3,743 Cr | 12.02 | |
| Mar2022 | ₹3,341 Cr | 15.62 | |
| Mar2021 | ₹2,890 Cr | 11.66 | |
| Mar2020 | ₹2,588 Cr | - | |
AJANTA PHARMA Operating Profit
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 49.63 % |
| 5 Yr CAGR | 14.44 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,172 Cr | 49.63 | |
| Mar2023 | ₹783 Cr | -15.72 | |
| Mar2022 | ₹929 Cr | -6.94 | |
| Mar2021 | ₹999 Cr | 46.13 | |
| Mar2020 | ₹683 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 33.06 % |
| 5 Yr CAGR | 1.35 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 27.85% | 33.06 | |
| Mar2023 | 20.93% | -24.74 | |
| Mar2022 | 27.81% | -19.53 | |
| Mar2021 | 34.56% | 30.91 | |
| Mar2020 | 26.4% | - | |
AJANTA PHARMA Profit After Tax
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 38.81 % |
| 5 Yr CAGR | 14.94 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹816 Cr | 38.81 | |
| Mar2023 | ₹588 Cr | -17.50 | |
| Mar2022 | ₹713 Cr | 8.99 | |
| Mar2021 | ₹654 Cr | 39.81 | |
| Mar2020 | ₹468 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 24.76 % |
| 5 Yr CAGR | -13.26 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 10.23 % | 24.76 | |
| Mar2023 | 8.2 % | -60.93 | |
| Mar2022 | 20.99 % | -5.32 | |
| Mar2021 | 22.17 % | 22.69 | |
| Mar2020 | 18.07 % | - | |
AJANTA PHARMA Earnings Per Share (EPS)
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 38.82 % |
| 5 Yr CAGR | 4.87 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹65 | 38.82 | |
| Mar2023 | ₹47 | -44.04 | |
| Mar2022 | ₹83 | 10.40 | |
| Mar2021 | ₹76 | 41.03 | |
| Mar2020 | ₹54 | - | |
AJANTA PHARMA Return on Capital Employed (ROCE)
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 42.76 % |
| 5 Yr CAGR | 4.10 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 32.22% | 42.76 | |
| Mar2023 | 22.57% | -23.15 | |
| Mar2022 | 29.37% | -8.79 | |
| Mar2021 | 32.2% | 17.35 | |
| Mar2020 | 27.44% | - | |
AJANTA PHARMA Share Price vs Sensex
| Current Share Price | : | ₹2,718.3 |
| Current MarketCap | : | ₹ 33,951.6 Cr |
| Updated EOD on | : | Feb 01,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AJANTA PHARMA | 5.7% |
-5.3% |
24.4% |
| SENSEX | 2.8% |
-3.1% |
9% |
AJANTA PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE 150 MIDCAP | 3.6% | -8.2% | 13.3% |
| S&P BSE 400 MIDSMALLCAP | 3.5% | -9.1% | 11.2% |
| S&P BSE MIDSMALLCAP | 3.4% | -9.9% | 12% |
| S&P BSE 500 | 3.2% | -5.4% | 9.7% |
| S&P BSE 250 LARGEMIDCAP | 3.2% | -4.8% | 10% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MID SMALL400 | 3.3% | -9.2% | 10.8% |
| NIFTY500 MULTICAP 50:25:25 | 3.3% | -6.8% | 10.3% |
| NIFTY MIDCAP150 | 3.2% | -7.9% | 12.3% |
| NIFTY 500 | 3.2% | -5.4% | 10.3% |
| NIFTY LARGE MIDCAP 250 | 3.2% | -5.9% | 11.3% |
You may also like the below Video Courses
FAQ about AJANTA PHARMA Financials
How the annual revenues of AJANTA PHARMA have changed ?
The Revenues of AJANTA PHARMA have increased by 12.45% YoY .
How the Earnings per Share (EPS) of AJANTA PHARMA have changed?
The Earnings Per Share (EPS) of AJANTA PHARMA has increased by 38.82 % YoY .
Check out Intrinsic Value of Peers of AJANTA PHARMA
Compare Stock Analytics of Peers of AJANTA PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
